|
1
|
de Vries MR, Simons KH, Jukema JW, Braun J
and Quax PH: Vein graft failure: From pathophysiology to clinical
outcomes. Nat Rev Cardiol. 13:451–470. 2016.PubMed/NCBI
|
|
2
|
Owens CD: Adaptive changes in autogenous
vein grafts for arterial reconstruction: Clinical implications. J
Vasc Surg. 51:736–746. 2010.PubMed/NCBI
|
|
3
|
Gasper WJ, Owens CD, Kim JM, Hills N,
Belkin M, Creager MA and Conte MS: Thirty-day vein remodeling is
predictive of midterm graft patency after lower extremity bypass. J
Vasc Surg. 57:9–18. 2013.PubMed/NCBI
|
|
4
|
Conte MS, Owens CD, Belkin M, Creager MA,
Edwards KL, Gasper WJ, Kenagy RD, LeBoeuf RC, Sobel M and Clowes A:
A single nucleotide polymorphism in the p27(Kip1) gene is
associated with primary patency of lower extremity vein bypass
grafts. J Vasc Surg. 57:1179–1185.e1-e2. 2013.PubMed/NCBI
|
|
5
|
Lu DY, Chen EY, Wong DJ, Yamamoto K,
Protack CD, Williams WT, Assi R, Hall MR, Sadaghianloo N and Dardik
A: Vein graft adaptation and fistula maturation in the arterial
environment. J Surg Res. 188:162–173. 2014.PubMed/NCBI
|
|
6
|
Hunter MJ and Chazin WJ: High level
expression and dimer characterization of the S100 EF-hand proteins,
migration inhibitory factor-related proteins 8 and 14. J Biol Chem.
273:12427–12435. 1998.PubMed/NCBI
|
|
7
|
Boyd JH, Kan B, Roberts H, Wang Y and
Walley KR: S100A8 and S100A9 mediate endotoxin-induced
cardiomyocyte dysfunction via the receptor for advanced glycation
end products. Circ Res. 102:1239–1246. 2008.PubMed/NCBI
|
|
8
|
Chang CC, Khan I, Tsai KL, Li H, Yang LW,
Chou RH and Yu C: Blocking the interaction between S100A9 and RAGE
V domain using CHAPS molecule: A novel route to drug development
against cell proliferation. Biochim Biophys Acta. 1864:1558–1569.
2016.PubMed/NCBI
|
|
9
|
Averill MM, Kerkhoff C and Bornfeldt KE:
S100A8 and S100A9 in cardiovascular biology and disease.
Arterioscler Thromb Vasc Biol. 32:223–229. 2012.PubMed/NCBI
|
|
10
|
Vogl T, Propper C, Hartmann M, Strey A,
Strupat K, van den Bos C, Sorg C and Roth J: S100A12 is expressed
exclusively by granulocytes and acts independently from MRP8 and
MRP14. J Biol Chem. 274:25291–25296. 1999.PubMed/NCBI
|
|
11
|
Marenholz I, Heizmann CW and Fritz G: S100
proteins in mouse and man: From evolution to function and pathology
(including an update of the nomenclature). Biochem Biophys Res
Commun. 322:1111–1122. 2004.PubMed/NCBI
|
|
12
|
Leclerc E, Fritz G, Vetter SW and Heizmann
CW: Binding of S100 proteins to RAGE: An update. Biochim Biophys
Acta. 1793:993–1007. 2009.PubMed/NCBI
|
|
13
|
Donato R, Cannon BR, Sorci G, Riuzzi F,
Hsu K, Weber DJ and Geczy CL: Functions of S100 proteins. Curr Mol
Med. 13:24–57. 2013.PubMed/NCBI
|
|
14
|
Gross SR, Sin CG, Barraclough R and
Rudland PS: Joining S100 proteins and migration: For better or for
worse, in sickness and in health. Cell Mol Life Sci. 71:1551–1579.
2014.PubMed/NCBI
|
|
15
|
Buyukterzi Z, Can U, Alpaydin S, Guzelant
A, Karaarslan S, Kocyigit D and Gurses KM: Enhanced S100A9 and
S100A12 expression in acute coronary syndrome. Biomark Med.
11:229–237. 2017.PubMed/NCBI
|
|
16
|
Wang S, Song R, Wang Z, Jing Z, Wang S and
Ma J: S100A8/A9 in Inflammation. Front Immunol.
9:12982018.PubMed/NCBI
|
|
17
|
Li Y, Chen B, Yang X, Zhang C, Jiao Y, Li
P, Liu Y, Li Z, Qiao B, Bond Lau W, et al: S100a8/a9 signaling
causes mitochondrial dysfunction and cardiomyocyte death in
response to ischemic/reperfusion injury. Circulation. 140:751–764.
2019.PubMed/NCBI
|
|
18
|
Stocca A, O'Toole D, Hynes N, Hynes SO,
Mashayekhi K, McGinley L, O'Connell E, Coleman C, Sultan S, Duffy
A, et al: A role for MRP8 in in stent restenosis in diabetes.
Atherosclerosis. 221:325–332. 2012.PubMed/NCBI
|
|
19
|
Li C, Li S, Jia C, Yang L, Song Z and Wang
Y: Low concentration of S100A8/9 promotes angiogenesis-related
activity of vascular endothelial cells: Bridges among inflammation,
angiogenesis, and tumorigenesis? Mediators Inflamm.
2012:2485742012.PubMed/NCBI
|
|
20
|
Ben Ali W, Bouhout I and Perrault LP: The
effect of storage solutions, gene therapy, and antiproliferative
agents on endothelial function and saphenous vein graft patency. J
Card Surg. 33:235–242. 2018.PubMed/NCBI
|
|
21
|
Xu X, Chen H, Zhu X, Ma Y, Liu Q, Xue Y,
Chu H, Wu W, Wang J and Zou H: S100A9 promotes human lung
fibroblast cells activation through receptor for advanced glycation
end-product-mediated extracellular-regulated kinase 1/2,
mitogen-activated protein-kinase and nuclear factor-κB-dependent
pathways. Clin Exp Immunol. 173:523–535. 2013.PubMed/NCBI
|
|
22
|
Ghavami S, Rashedi I, Dattilo BM, Eshraghi
M, Chazin WJ, Hashemi M, Wesselborg S, Kerkhoff C and Los M:
S100A8/A9 at low concentration promotes tumor cell growth via RAGE
ligation and MAP kinase-dependent pathway. J Leukoc Biol.
83:1484–1492. 2008.PubMed/NCBI
|
|
23
|
Owens CD, Gasper WJ, Rahman AS and Conte
MS: Vein graft failure. J Vasc Surg. 61:203–216. 2015.PubMed/NCBI
|
|
24
|
Jaffe EA, Nachman RL, Becker CG and Minick
CR: Culture of human endothelial cells derived from umbilical
veins. Identification by morphologic and immunologic criteria. J
Clin Invest. 52:2745–2756. 1973.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI
|
|
26
|
Wang Q, Wan L, Liu L and Liu J: Role of
the mTOR signalling pathway in experimental rabbit vein grafts.
Heart Lung Circ. 25:1124–1132. 2016.PubMed/NCBI
|
|
27
|
Ziegler ME, Hatch MM, Wu N, Muawad SA and
Hughes CC: mTORC2 mediates CXCL12-induced angiogenesis.
Angiogenesis. 19:359–371. 2016.PubMed/NCBI
|
|
28
|
Lieberthal W and Levine JS: Mammalian
target of rapamycin and the kidney. I. The signaling pathway. Am J
Physiol Renal Physiol. 303:F1–F10. 2012.PubMed/NCBI
|
|
29
|
Wang S, Amato KR, Song W, Youngblood V,
Lee K, Boothby M, Brantley-Sieders DM and Chen J: Regulation of
endothelial cell proliferation and vascular assembly through
distinct mTORC2 signaling pathways. Mol Cell Biol. 35:1299–1313.
2015.PubMed/NCBI
|
|
30
|
Tandon M, Chen Z and Pratap J: Runx2
activates PI3K/Akt signaling via mTORC2 regulation in invasive
breast cancer cells. Breast Cancer Res. 16:R162014.PubMed/NCBI
|
|
31
|
Li X, Sun Y, Huang S, Chen Y, Chen X, Li
M, Si X, He X, Zheng H, Zhong L, et al: Inhibition of AZIN2-sv
induces neovascularization and improves prognosis after myocardial
infarction by blocking ubiquitin-dependent talin1 degradation and
activating the Akt pathway. EBioMedicine. 39:69–82. 2019.PubMed/NCBI
|
|
32
|
Lipton JO and Sahin M: The neurology of
mTOR. Neuron. 84:275–291. 2014.PubMed/NCBI
|
|
33
|
Yan SF, Ramasamy R and Schmidt AM: The
RAGE axis: A fundamental mechanism signaling danger to the
vulnerable vasculature. Circ Res. 106:842–853. 2010.PubMed/NCBI
|
|
34
|
Palanissami G and Paul SFD: RAGE and its
ligands: Molecular interplay between glycation, inflammation, and
hallmarks of cancer-a review. Horm Cancer. 9:295–325.
2018.PubMed/NCBI
|
|
35
|
Yamagishi SI and Matsui T: Role of ligands
of receptor for advanced glycation end products (RAGE) in
peripheral artery disease. Rejuvenation Res. 21:456–463.
2018.PubMed/NCBI
|
|
36
|
Pruenster M, Vogl T, Roth J and Sperandio
M: S100A8/A9: From basic science to clinical application. Pharmacol
Ther. 167:120–131. 2016.PubMed/NCBI
|
|
37
|
Roth J, Vogl T, Sorg C and Sunderkötter C:
Phagocyte-specific S100 proteins: A novel group of proinflammatory
molecules. Trends Immunol. 24:155–158. 2003.PubMed/NCBI
|
|
38
|
Kang R, Tang D, Schapiro NE, Livesey KM,
Farkas A, Loughran P, Bierhaus A, Lotze MT and Zeh HJ: The receptor
for advanced glycation end products (RAGE) sustains autophagy and
limits apoptosis, promoting pancreatic tumor cell survival. Cell
Death Differ. 17:666–676. 2010.PubMed/NCBI
|
|
39
|
Hou X, Hu Z, Xu H, Xu J, Zhang S, Zhong Y,
He X and Wang N: Advanced glycation endproducts trigger autophagy
in cadiomyocyte via RAGE/PI3K/AKT/mTOR pathway. Cardiovasc
Diabetol. 13:782014.PubMed/NCBI
|
|
40
|
Chen J, Zhao D, Zhu M, Zhang M, Hou X,
Ding W, Sun S, Bu W, Feng L, Ma S and Jia X: Paeoniflorin
ameliorates AGEs-induced mesangial cell injury through inhibiting
RAGE/mTOR/autophagy pathway. Biomed Pharmacother. 89:1362–1369.
2017.PubMed/NCBI
|
|
41
|
Li W, Petrimpol M, Molle KD, Hall MN,
Battegay EJ and Humar R: Hypoxia-induced endothelial proliferation
requires both mTORC1 and mTORC2. Circ Res. 100:79–87.
2007.PubMed/NCBI
|
|
42
|
Sarbassov DD, Ali SM, Sengupta S, Sheen
JH, Hsu PP, Bagley AF, Markhard AL and Sabatini DM: Prolonged
rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell.
22:159–168. 2006.PubMed/NCBI
|
|
43
|
Yi T, Fogal B, Hao Z, Tobiasova Z, Wang C,
Rao DA, Al-Lamki RS, Kirkiles-Smith NC, Kulkarni S, Bradley JR, et
al: Reperfusion injury intensifies the adaptive human T cell
alloresponse in a human-mouse chimeric artery model. Arterioscler
Thromb Vasc Biol. 32:353–360. 2011.PubMed/NCBI
|
